5-Fluorouracil, folinic acid and cisplatin in advanced colorectal cancer: a pilot study. 1995

N Tsavaris, and K Tentas, and C Bacoyiannis, and M Katsikas, and N Sakelaropoulos, and C Kosmas, and D Daliani, and P Kosmidis
Second Department of Medical Oncology, Metaxa' Cancer Hospital, Piraeus, Greece.

The combination of 5-fluorouracil (5-FU) and folinic acid (FA) has demonstrated activity in colorectal cancer (CC). Cisplatin is reported to have synergistic activity with 5-FU. We examined the combination FA + 5-FU + cisplatin in patients who had previously received chemotherapy with FA + 5-FU and relapsed. Two months after the last dose of FA + 5-FU and documentation of relapse, patients continued with the regimen consisting of cisplatin 20 mg/m2 in 15 min i.v. infusion followed by FA 500 mg/m2 in 1 h i.v. infusion, in the middle of which 5-FU 500 mg/m2 i.v. bolus was administered, with adequate post-hydration. This was repeated weekly for 4 weeks followed by a 2 week rest, for a maximum of six cycles. A total of 30 patients with CC that had relapsed to the combination of FA + 5-FU were treated; 23 had previous surgery and none had radiotherapy. Local recurrence was found in eight patients, metastases in the liver in 21, in lymph nodes in six, lung six and peritoneal metastases in seven. Seven patients responded partially. Toxicity requiring dose reduction or discontinuation of treatment included neutropenia 42% (grade 3:7%), mucositis 28% (grade 1:2), diarrhea 63% (Grade 3:10%), nausea-vomiting 55% (Grade 3:10%), increased creatinine value in three patients and peripheral neuropathy in two patients. We conclude that evaluation of this regimen shows substantial toxicity, with satisfactory response as a second line chemotherapy in these heavily pretreated patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D001772 Blood Cell Count The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES. Blood Cell Number,Blood Count, Complete,Blood Cell Counts,Blood Cell Numbers,Blood Counts, Complete,Complete Blood Count,Complete Blood Counts,Count, Blood Cell,Count, Complete Blood,Counts, Blood Cell,Counts, Complete Blood,Number, Blood Cell,Numbers, Blood Cell
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

N Tsavaris, and K Tentas, and C Bacoyiannis, and M Katsikas, and N Sakelaropoulos, and C Kosmas, and D Daliani, and P Kosmidis
January 1988, Cancer investigation,
N Tsavaris, and K Tentas, and C Bacoyiannis, and M Katsikas, and N Sakelaropoulos, and C Kosmas, and D Daliani, and P Kosmidis
January 2000, Anticancer research,
N Tsavaris, and K Tentas, and C Bacoyiannis, and M Katsikas, and N Sakelaropoulos, and C Kosmas, and D Daliani, and P Kosmidis
January 1995, Anticancer research,
N Tsavaris, and K Tentas, and C Bacoyiannis, and M Katsikas, and N Sakelaropoulos, and C Kosmas, and D Daliani, and P Kosmidis
January 1989, Oncology,
N Tsavaris, and K Tentas, and C Bacoyiannis, and M Katsikas, and N Sakelaropoulos, and C Kosmas, and D Daliani, and P Kosmidis
January 1988, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
N Tsavaris, and K Tentas, and C Bacoyiannis, and M Katsikas, and N Sakelaropoulos, and C Kosmas, and D Daliani, and P Kosmidis
October 1988, European journal of cancer & clinical oncology,
N Tsavaris, and K Tentas, and C Bacoyiannis, and M Katsikas, and N Sakelaropoulos, and C Kosmas, and D Daliani, and P Kosmidis
January 1997, European urology,
N Tsavaris, and K Tentas, and C Bacoyiannis, and M Katsikas, and N Sakelaropoulos, and C Kosmas, and D Daliani, and P Kosmidis
January 1999, Acta oncologica (Stockholm, Sweden),
N Tsavaris, and K Tentas, and C Bacoyiannis, and M Katsikas, and N Sakelaropoulos, and C Kosmas, and D Daliani, and P Kosmidis
September 1988, European journal of cancer & clinical oncology,
N Tsavaris, and K Tentas, and C Bacoyiannis, and M Katsikas, and N Sakelaropoulos, and C Kosmas, and D Daliani, and P Kosmidis
February 1993, Journal of chemotherapy (Florence, Italy),
Copied contents to your clipboard!